Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Carbon Biosciences

Request full access

Novel parvovirus gene therapies for difficult-to-treat diseases

Waltham, United StatesFounded 2021Biotech & Life Sciences

About Carbon Biosciences

Carbon Biosciences is a preclinical-stage biotechnology company founded in 2021 that is developing novel gene therapies derived from parvoviruses. The company was established by the investment firm Longwood Fund along with gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. Additional co-founders include David Steinberg, Jianming Qiu, Ph.D., Ziying Yan, Ph.D., Sebastian Aguirre, Ph.D., and Lucy Liu, Ph.D. The company emerged from stealth in June 2022 with a $38 million Series A financing round led by Agent Capital, with participation from Longwood Fund, Astellas Venture Management, the Cystic Fibrosis Foundation, and others.

The company's proprietary platform focuses on leveraging novel parvoviruses, which are distinct from the commonly used adeno-associated viruses (AAVs) in gene therapy. This approach aims to address several key limitations of current gene therapy technologies. Carbon's vectors are designed to carry larger genetic payloads, target specific tissues with greater precision, and have minimal pre-existing neutralizing immunity in the population. This allows for the potential to re-dose patients, which is a significant challenge with AAV-based therapies due to the immune response they generate. A recent collaboration announced in June 2025 with WhiteLab Genomics aims to use artificial intelligence to further engineer Carbon's parvovirus capsids to optimize delivery to specific cell types and accelerate development.

Carbon Biosciences' business model is centered on developing a pipeline of gene therapy candidates for genetic diseases. Its initial lead program, CGT-001, targets cystic fibrosis (CF) and is designed to deliver the full-length CFTR gene, which is too large for conventional AAV vectors, specifically to lung tissue. The company's work in CF is supported by a collaborative agreement with the Cystic Fibrosis Foundation. Beyond CF, the company is expanding its pipeline to include treatments for pulmonary and cardiac diseases, utilizing its CBN-1000 and CBN-1100 capsids. The company plans to use its funding to advance these programs through IND-enabling studies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
59.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2022 $38M $152M Longwood Fund · Agent Capital · Solasta Ventures · Cystic Fibrosis Foundation ↗
EARLY VCOther financing Jan 2022 $38M $152M Undisclosed ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Carbon Biosciences website traffic

Latest recorded traffic for Carbon Biosciences is 1.2K monthly website visits, up 179.1% over the last three months. Carbon Biosciences's team declined 31.3% over the past year.

Latest monthly visits1.2K 3-month web change+179.1% 1-year team growth-31.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Carbon Biosciences in the Waltham ecosystem

Live from Dealroom

The Carbon Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Longwood Fund
  • Agent Capital
  • Solasta Ventures
  • Cystic Fibrosis Foundation
  • Astellas Venture
  • UTokyo Innovation Platform

Other known investors1 additional known investor

  • The University of Tokyo
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States94.1%
🇯🇵 Japan5.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Carbon Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Carbon Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.